Marks Gilbert Lynn 4

What Happened

• Marks Gilbert Lynn, a director of AN2 Therapeutics (ANTX), acquired 44,769 shares on March 19, 2026 via derivative transactions (exercise of options) and immediately disposed of the same 44,769 shares to the issuer. The repriced exercise price is $3.91 per share, implying an aggregate exercise amount of about $175,047. The option exercised was fully vested and the board approved the repricing on March 19, 2026.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 23, 2026 (timely within two business days).
• Shares acquired (derivative): 10,665; 10,362; 23,742 — total 44,769. Same amounts were immediately disposed to the issuer.
• Exercise price reported: $3.91 per share; total cash/consideration implied ≈ $175,047.
• Footnotes: (F1) $3.91 is the repriced exercise price; it may revert to the original exercise price under certain conditions before the "Premium End Date" (earliest of Sept 19, 2027, a change in control, or death/disability). (F2) Option was fully vested. (F3) Board approved the repricing on March 19, 2026.
• Shares owned after the transaction are not specified in the provided details.

Context

• The filing shows derivative acquisitions and immediate dispositions to the issuer — a common structure when options are exercised and shares are surrendered to the company (often to cover exercise costs or tax withholding), rather than an open-market sale or purchase. This transaction should be interpreted as an option exercise event rather than a market-directional purchase.